Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 5:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Low dose Omega 3 Clear all
Completed Phase 2 Interventional Results available

Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures

NCT00871377
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, High Dose Fish Oil, Low Dose Fish Oil
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder

NCT00511810
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Low Dose Fish Oil, High Dose Fish Oil
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Omega-3 Supplementation and Mental Health in College Students

NCT07391254
View directory record Official record
Conditions
Mental Health, Vitamin D
Interventions
Placebo, Low dose Omega 3, High dose Omega 3
Dietary Supplement
Lead sponsor
University of Colorado, Colorado Springs
Other
Eligibility
18 Years to 27 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 11, 2026, 5:23 PM EDT
Active, not recruiting Not applicable Interventional

Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention

NCT02295059
View directory record Official record
Conditions
Breast Cancer
Interventions
omega 3 fatty acids
Dietary Supplement
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
Duarte, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Omega-3 Fatty Acids on Markers of Inflammation

NCT01129050
View directory record Official record
Conditions
Obesity, Hypertriglyceridemia, Insulin Resistance, Hypertension
Interventions
Fish Oil, Flaxseed Oil, Placebo
Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

Fatty Acid Supplementation in Children With ASD

NCT03550209
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
LCPUFA Oil Supplement, Canola Oil Placebo
Drug · Dietary Supplement
Lead sponsor
Sarah Keim
Other
Eligibility
2 Years to 6 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA

NCT02113163
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent, Hypertriglyceridemia
Interventions
Metformin Eicosapentaenoate, Metformin HCl and Vascepa
Drug
Lead sponsor
Thetis Pharmaceuticals LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study

NCT02676466
View directory record Official record
Conditions
Inflammation
Interventions
Omega-3 fish oil, Losartan, Corn Oil (Fish oil Placebo), Cellulose Based (Losartan Placebo)
Dietary Supplement · Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
70 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Gainesville, Florida • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Not applicable Interventional

Essential Fatty Acids for Major Depression

NCT00256412
View directory record Official record
Conditions
Major Depression
Interventions
Eicosapentaenoic acid (EPA) 0.7 grams/day or 1.5 grams/day, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 4, 2008 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Not applicable Interventional Results available

Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors

NCT02352779
View directory record Official record
Conditions
Breast Carcinoma, Cancer, Fatigue
Interventions
Omega-3 Fatty Acid, Placebo, Questionnaire Administration, Laboratory Biomarker Analysis
Dietary Supplement · Other
Lead sponsor
Gary Morrow
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Wichita, Kansas • Grand Rapids, Michigan • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation

NCT01208961
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Epanova (4 g) and Lovaza (4 g), Lovaza (4 g) and Epanova (4 g)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 14, 2015 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of DHA on Periodontitis

NCT01976806
View directory record Official record
Conditions
Periodontitis, Gingivitis, Inflammation
Interventions
Aspirin, Docosahexaenoic acid, Placebo (for Docosahexaenoic acid)
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
40 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals

NCT01431690
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
warfarin, omefas, omega-3-acid ethyl esters
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention

NCT00723398
View directory record Official record
Conditions
Breast Cancer
Interventions
Lovaza 4gm oral, Raloxifene 60 Mg Oral Tablet, Raloxifene 30 Mg Oral Tablet, Lovaza 4gm & Raloxifene 30mg
Dietary Supplement · Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
35 Years to 70 Years · Female only
Enrollment
266 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Not applicable Interventional Results available

Omega 3 Fatty Acids in the Treatment of Children With Autism Spectrum Disorders

NCT00467818
View directory record Official record
Conditions
Autism
Interventions
Omega 3 fatty acids, Placebo
Drug · Other
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
5 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Sep 11, 2026, 5:23 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

NCT06195306
View directory record Official record
Conditions
Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions
Biospecimen Collection, Mammography, Omega-3-Acid Ethyl Esters, Questionnaire Administration, Random Periareolar Fine-Needle Aspiration, Tamoxifen
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
45 Years to 74 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
3
States / cities
Kansas City, Kansas • Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nutrition Interventions for Cognitive Enhancement

NCT03841539
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Mediterranean Diet, Study Supplement, Low-fat Diet
Behavioral · Dietary Supplement
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
65 Years and older
Enrollment
209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Sep 11, 2026, 5:23 PM EDT
Not listed Phase 4 Interventional

A Prospective Study to Evaluate the Raindrop Near Vision Inlay in Presbyopic Patients With Treatments to Optimize the Ocular Surface Before Implantation

NCT03126877
View directory record Official record
Conditions
Presbyopia
Interventions
Mitomycin C, Raindrop Near Vision Inlay
Drug · Device
Lead sponsor
Whitten Laser Eye
Other
Eligibility
41 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Sep 11, 2026, 5:23 PM EDT